


## **Supplementary Materials:**




**Figure S1.** Alpha diversity analysis of control, non-erosive reflux disease (NERD), reflux esophagitis (RE), Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC) using Chao1 richness estimator and Shannon diversity index.




**Figure S2.** Non-metric multi-dimensional scaling (nMDS) plot for Bray-Curtis dissimilarity (abundance and composition) analysis and Jaccard (presence/absence) analysis of control, non-erosive reflux disease (NERD), reflux esophagitis (RE), Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC).



**Figure S3.** Microbiota phylum composition within each group: control, non-erosive reflux disease (NERD), reflux esophagitis (RE), Barrett's esophagus (BE), and esophageal adenocarcinoma (EAC).



**Figure S4.** Differences in bacterial phylum composition between proton pump inhibitor treatment in non-erosive reflux disease (NERD), reflux esophagitis (RE), and Barrett's esophagus (BE) disease phenotypes.



**Figure S5.** (**A**) protein disulfide isomerase and (**B**) serum albumin were found differentially expressed between proton pump inhibitor (PPI) treated and untreated mucosal proteomic samples in nonerosive reflux diseases (NERD), reflux esophagitis (RE) and Barrett's esophagus (BE).